Johannes F E Mann Selected Research

Percutaneous Coronary Intervention

11/2009	Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention.
1/2008	Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johannes F E Mann Research Topics

Disease

36	Type 2 Diabetes Mellitus (MODY) 01/2023 - 11/2003
28	Cardiovascular Diseases (Cardiovascular Disease) 11/2023 - 01/2002
26	Chronic Renal Insufficiency 02/2023 - 04/2002
18	Albuminuria 01/2023 - 03/2003
16	Proteinuria 10/2020 - 03/2003
15	Stroke (Strokes) 10/2023 - 07/2005
15	Heart Failure 10/2023 - 03/2003
15	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 11/2003
14	Myocardial Infarction 10/2023 - 07/2005
13	Renal Insufficiency (Renal Failure) 01/2023 - 01/2000
9	Vascular Diseases (Vascular Disease) 01/2021 - 03/2003
6	Kidney Diseases (Kidney Disease) 01/2022 - 02/2006
6	Hypertension (High Blood Pressure) 01/2021 - 01/2002
5	Hyperkalemia 12/2014 - 01/2002
4	Body Weight (Weight, Body) 01/2023 - 03/2014
4	Diabetic Nephropathies (Diabetic Nephropathy) 01/2017 - 07/2009
4	Acute Kidney Injury (Acute Renal Failure) 01/2017 - 01/2002
3	Insulin Resistance 10/2023 - 01/2002
3	Hypoglycemia (Reactive Hypoglycemia) 01/2020 - 01/2020
3	Hemorrhage 10/2012 - 04/2007
2	Coronary Artery Disease (Coronary Atherosclerosis) 01/2023 - 02/2002
2	Disease Progression 01/2023 - 02/2006
2	Pancreatitis 01/2016 - 11/2014
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2023
1	Peripheral Arterial Disease 01/2023
1	Peripheral Vascular Diseases (Peripheral Vascular Disease) 01/2020
1	IGA Glomerulonephritis (IGA Nephropathy) 01/2018
1	Prediabetic State (Prediabetes) 01/2018
1	Death (Near-Death Experience) 01/2016
1	Hyperphosphatemia 06/2015
1	Shock 01/2015
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 01/2015
1	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2015

Drug/Important Bio-Agent (IBA)

30	CreatinineIBA 01/2022 - 01/2002
19	Ramipril (Altace)FDA LinkGeneric 01/2022 - 01/2002
16	Telmisartan (Micardis)FDA Link 01/2022 - 08/2008
15	Liraglutide FDA Link 01/2022 - 11/2013
13	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 04/2015 - 01/2002
8	AlbuminsIBA 01/2022 - 02/2004
8	Angiotensin Receptor AntagonistsIBA 04/2015 - 09/2004
5	semaglutideIBA 01/2023 - 11/2020
5	SodiumIBA 01/2020 - 10/2013
4	omega-Chloroacetophenone (Mace)IBA 01/2023 - 01/2008
4	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2023 - 01/2021
4	Glucagon-Like Peptide-1 ReceptorIBA 01/2023 - 12/2018
4	LDL CholesterolIBA 01/2022 - 01/2004
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016 - 03/2004
4	Proteins (Proteins, Gene)FDA Link 12/2015 - 01/2008
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 02/2013 - 02/2004
4	Lipoprotein(a)IBA 02/2006 - 01/2000
3	Glucose (Dextrose)FDA LinkGeneric 10/2023 - 07/2014
3	Triglycerides (Triacylglycerol)IBA 10/2023 - 01/2004
3	dapagliflozinIBA 01/2022 - 10/2020
3	Hemoglobins (Hemoglobin)IBA 01/2022 - 02/2006
3	Glucagon-Like Peptide 1 (GLP 1)IBA 11/2020 - 01/2016
3	Insulin (Novolin)FDA Link 01/2020 - 11/2013
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 07/2015
3	Insulin Glargine (Lantus)FDA Link 01/2018 - 07/2014
3	Atorvastatin (Lipitor)FDA Link 01/2016 - 01/2004
3	HomocysteineIBA 02/2008 - 01/2002
2	LDL Lipoproteins (beta Lipoproteins)IBA 10/2023 - 01/2022
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 02/2023 - 01/2008
2	empagliflozinIBA 01/2023 - 01/2023
2	PotassiumIBA 01/2022 - 12/2014
2	HDL CholesterolIBA 01/2022 - 01/2004
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2022 - 01/2020
2	Dietary SodiumIBA 01/2020 - 12/2016
2	Phosphates (Orthophosphate)IBA 06/2015 - 09/2007
2	Endothelin Receptor AntagonistsIBA 03/2014 - 03/2010
2	AvosentanIBA 03/2014 - 03/2010
2	Hypoglycemic Agents (Hypoglycemics)IBA 11/2013 - 02/2004
2	Clopidogrel (Plavix)FDA Link 01/2008 - 04/2007
2	apolipoprotein A-IV (apolipoprotein AIV)IBA 02/2006 - 02/2002
2	Arginine (L-Arginine)FDA Link 05/2003 - 01/2002
1	oxidized low density lipoproteinIBA 10/2023
1	finerenoneIBA 01/2023
1	HDL LipoproteinsIBA 01/2022
1	IncretinsIBA 01/2021
1	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2021
1	SaltsIBA 01/2020
1	LinagliptinIBA 01/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018
1	Prednisolone (Predate)FDA LinkGeneric 01/2018
1	Azathioprine (Imuran)FDA LinkGeneric 01/2018
1	Blood Proteins (Serum Proteins)IBA 01/2018
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2018
1	TabletsIBA 06/2015
1	sucroferric oxyhydroxideIBA 06/2015
1	Sevelamer (RenaGel)FDA Link 06/2015
1	Phosphorus (Red Phosphorus)IBA 06/2015
1	Hormones (Hormone)IBA 01/2015

Therapy/Procedure

12	Therapeutics 11/2023 - 01/2008
4	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2023 - 02/2006
4	Renal Dialysis (Hemodialysis) 01/2016 - 01/2004
2	Aftercare (After-Treatment) 01/2021 - 03/2014
2	Percutaneous Coronary Intervention 11/2009 - 01/2008
1	Continuous Renal Replacement Therapy 01/2021
1	Secondary Prevention 01/2021
1	Diet Therapy (Therapy, Diet) 07/2016
1	Peritoneal Dialysis 06/2015